Biotechs' financing deals help with development costs

05/8/2006 | American City Business Journals

Biotechnology companies already burdened with funding treatments nearing market approval are entering into agreements with private-equity firms to create separate entities to help shoulder the risk and cost associated with developing promising early-stage drugs. This financing mechanism fell out of favor amid some scandals involving off-balance sheet arrangements, but the new deals are transparent and the entities' financial dealings are covered in the parent company's statements.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX